drugset / Trial / NCT02192346
α-TEA in Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood. Additional goals of this study are to monitor the effect on tumors, to check for specific immune cells circulating in the blood, and to see if there are certain features of tumors that make it possible to predict the response to α-TEA.
Timeline
- Start
- 2014-08-04
- Primary completion
- 2017-12-11
- Completion
- 2018-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpha-tocopheryloxyacetic Acid | Small molecule | 2.4 mg/kg | Oral |
| Subject | Alpha-tocopheryloxyacetic Acid | Small molecule | 4.8 mg/kg | Oral |
| Subject | Alpha-tocopheryloxyacetic Acid | Small molecule | 8 mg/kg | Oral |
| Subject | Alpha-tocopheryloxyacetic Acid | Small molecule | 9.6 mg/kg | Oral |
| Subject | Alpha-tocopheryloxyacetic Acid | Small molecule | 12 mg/kg | Oral |
| Subject | Alpha-tocopheryloxyacetic Acid | Small molecule | 16.8 mg/kg | Oral |
| Subject | Alpha-tocopheryloxyacetic Acid | Small molecule | 19.2 mg/kg | Oral |
| Subject | Alpha-tocopheryloxyacetic Acid | Small molecule | 22.3 mg/kg | Oral |
| Subject | Alpha-tocopheryloxyacetic Acid | Small molecule | 26.8 mg/kg | Oral |